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Introduction {#sec1}
============

The gastrointestinal tract is colonized by a high density of commensal bacteria and is a major site of pathogen entry ([@bib42]) requiring robust barrier function. Short chain fatty acids (SCFAs) are derived from bacterial fermentation of dietary fibers in the colonic lumen. The SCFAs butyrate, propionate, and acetate promote intestinal epithelial barrier function and regulate the host mucosal immune system ([@bib57]). For example, butyrate serves as a primary energy source for intestinal epithelial cells, the first line of cellular defense against invading pathogens. Butyrate also regulates stem cell turnover in intestinal epithelial crypts ([@bib28]). SCFAs, and in particular butyrate also promote regulatory T cells (Treg) in the colon by inhibiting histone deacetylase (HDAC) activity at the *Foxp3* locus ([@bib3], [@bib19], [@bib46]). Furthermore, exposure of peripheral blood mononuclear cells such as neutrophils, macrophages, and dendritic cells to SCFAs or other HDAC inhibitors, such as trichostatin (TSA), inhibits inflammatory cytokine production ([@bib11], [@bib51], [@bib56]).

Mouse models of intestinal inflammation suggest that butyrate plays an immune regulatory role *in vivo* ([@bib19]). This is potentially relevant for human immunopathology since reduced numbers of butyrate-producing bacteria were found in the gut mucosa and in fecal samples from patients with inflammatory bowel disease (IBD) or colon cancer ([@bib17], [@bib58]).

Intestinal phagocytes, and tissue-resident macrophages in particular, act as an innate barrier in the intestine by clearing invading bacteria. Malfunctioning of this pathway is involved in the pathogenesis of IBD since defective microbicidal responses were identified in polygenic and monogenic forms of IBD ([@bib40], [@bib50]). In contrast to macrophages found in other organs, intestinal macrophages are largely replenished from blood monocytes ([@bib5]). Thus, circulating monocytes enter the gut and undergo final differentiation in the lamina propria to become mature, highly phagocytic macrophages capable of bactericidal activity via mechanisms such as NADPH-oxidase-derived reactive oxygen species (ROS) and antimicrobial peptides and proteins ([@bib5], [@bib47], [@bib54]). The bacterial pathways that shape macrophage host defense in the intestine are poorly understood. Here we have investigated the ability of SCFAs to influence macrophage function. We show that SCFAs induce metabolic and transcriptional changes in macrophages, which enhances their bactericidal functions.

Results {#sec2}
=======

Butyrate Exposure during Macrophage Differentiation Enhances Antimicrobial Activity {#sec2.1}
-----------------------------------------------------------------------------------

To assess the impact of SCFAs on human macrophages, we differentiated peripheral blood-derived CD14^+^ monocytes with macrophage colony-stimulating factor (M-CSF) in the absence (control macrophages) or presence of butyrate (butyrate macrophages), propionate (propionate macrophages), or acetate (acetate macrophages). The presence of SCFAs during macrophage differentiation did not affect key macrophage characteristics such as morphology and surface expression of CD11c and HLA-DR ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). However, SCFAs did affect the antimicrobial function of macrophages assessed in a gentamicin protection assay using a range of bacteria including gram negative (*Salmonella enterica* serovar Typhimurium, later on referred to as *Salmonella*); Crohn's disease-associated adherent-invasive *Eschericha coli* (*AIEC*), and *Citrobacter rodentium* (*C. rodentium*) and gram-positive *Staphylococcus aureus* (*S. aureus*) microbes ([Figures 1](#fig1){ref-type="fig"}A--1D and [Figure S1](#mmc1){ref-type="supplementary-material"}B). As the anti-microbial effect was strongest with butyrate as opposed to proprionate and not observed with acetate, butyrate was studied further ([Figure 1](#fig1){ref-type="fig"}E and [Figures S1](#mmc1){ref-type="supplementary-material"}C--S1E).Figure 1Increased Antimicrobial Activity by Macrophages Differentiated in Presence of Butyrate(A--H) Gentamicin protection assay on control macrophages and butyrate macrophages with a range of different bacteria. Macrophages were infected for 1 h with *Salmonella enterica* serovar Typhimurium (*Salmonella*) (A, E--H), *adherent-invasive Escherichia coli* (AIEC) (B), *Staphylococcus aureus* (*S. aureus*) (C) or *Citrobacter rodentium* (*C. rodentium*; D) followed by gentamicin treatment for 2 h before cell lysis. Values represent absolute CFU counts. Each dot is representative of one donor. Representative image of agar plate showing *Salmonella* CFU (A, right).(E) Gentamicin protection assay on macrophages treated with different SCFAs.(F) Kinetics of elimination of *Salmonella* by control macrophages and butyrate macrophages.(G) Short-term butyrate treatment: macrophages were treated for 3 h with butyrate prior to the gentamicin protection assay.(H) Butyrate macrophages were cultured in the absence of butyrate for 24 h prior to the gentamicin protection assay.Each dot represents one independent donor, experiments were repeated 3--8 times. Statistical significance was determined using Mann-Whitney U test ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.Please also see [Figure S1](#mmc1){ref-type="supplementary-material"}.

We next investigated the kinetics of antibacterial activity, cytokine secretion, phagocytic capacity, and apoptosis in control macrophages and butyrate macrophages. Butyrate macrophages displayed significantly increased elimination of intracellular *Salmonella* as early as 30 min after infection, and this was maintained over the 3 h duration of the gentamicin protection assay ([Figure 1](#fig1){ref-type="fig"}F). Despite altered bacterial clearance, control macrophages and butyrate macrophages displayed similar expression of *IL1B* and *TNF* mRNA and protein following 3 h of *Salmonella* infection ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G), whereas *IL10* expression was reduced in butyrate macrophages ([Figure S1](#mmc1){ref-type="supplementary-material"}H). In contrast to the long-term exposure of butyrate during the differentiation process, incubation of control macrophages with butyrate for 3 h prior to the gentamicin protection assay did not induce a significant reduction in CFU compared to untreated control macrophages ([Figure 1](#fig1){ref-type="fig"}G). After 24 h incubation in butyrate-free media, butyrate macrophages retained enhanced antimicrobial activity, indicating that this response does not require butyrate at the time of infection ([Figure 1](#fig1){ref-type="fig"}H). The reduced bacterial load was not due to reduced phagocytosis as butyrate macrophages showed normal ingestion of FITC beads coated with human IgG and uptake of non-opsonised GFP-*Salmonella* over 90 min. In addition, they showed similar mRNA expression of the phagocytic receptors *MARCO* and *CLEC7A* compared to control ([Figures S1](#mmc1){ref-type="supplementary-material"}I--S1L). Reduced numbers of bacteria in butyrate macrophages was not a consequence of increased cell death as the percentage of apoptotic cells was also similar between butyrate macrophages and control macrophages ([Figures S1](#mmc1){ref-type="supplementary-material"}M and S1N). Taken together, these results show that the presence of butyrate during the differentiation of macrophages induces long-lasting antimicrobial activity without affecting phagocytosis, inflammatory cytokine production, or apoptosis.

Butyrate Alters Metabolism and Induces mTOR Dependent LC3-Associated Antimicrobial Clearance in Macrophages {#sec2.2}
-----------------------------------------------------------------------------------------------------------

As butyrate is a key energy source for epithelial cells ([@bib57]) and relevant amounts of butyrate are likely present in the lamina propria as suggested by portal vein concentrations ([@bib52]), we tested whether butyrate exposure alters macrophage metabolism. Butyrate macrophages showed a decreased extracellular acidification rate (ECAR) in comparison to control macrophages ([Figure 2](#fig2){ref-type="fig"}A). Glycolysis, glycolytic capacity and glycolytic reserve were also significantly reduced in butyrate macrophages ([Figures 2](#fig2){ref-type="fig"}B--2D). To explore the metabolic pathways modulated by butyrate, we performed a metabolomic analysis by liquid chromatography--mass spectrometry. This confirmed substantial changes in the glycolysis pathway including a reduced glucose concentration ([Figure 2](#fig2){ref-type="fig"}E and [Figure S2](#mmc1){ref-type="supplementary-material"}A). This is unlikely due to reduced glucose uptake as 2NBDG uptake in control and butyrate macrophages was similar ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Since we found similar mitochondrial oxidative phosphorylation (respiration, proton leak, oxygen consumption rate) between control and butyrate macrophages, the switch in glucose metabolism was not compensated for by increased mitochondrial energy metabolism ([Figures S2](#mmc1){ref-type="supplementary-material"}C--S2H).Figure 2Increase of Antimicrobial LC3-Associated Immune Defense in Butyrate Macrophages(A) Extracellular acidification rate (ECAR) measured at steady state in control and butyrate macrophages. Data represent the mean of nine biological replicates from three independent experiments.(B--D) Quantification of glycolysis (B), glycolytic capacity (C) and glycolytic reserve (D).(E) Heatmap of metabolites that were significantly higher or lower in control and butyrate macrophages as detected by mass-spectrometry (left panel). Results are from five healthy donors. Right panel: Fold change of all significantly higher or lower metabolites in control macrophages (black closed circles) and butyrate macrophages (red closed circles).(F) AMPK phosphorylation (Thr172) measured by ELISA (n = 4 individual donors).(G) Percentage of pS6 (left) and representative blot of phosphorylation and quantification (right) of the ribosomal protein S6 and β-actin in control and butyrate macrophages at steady state.(H) Gentamicin protection assay performed on control macrophages, butyrate macrophages, and butyrate macrophages treated for 2 h with the mTOR activator MHY1485 (20 mM).(I) Representative immunoblot of the expression of LC3-II, P62, and β-actin at steady state or after 2 h infection with *Salmonella*.(J and K) Protein quantification performed by ImageJ of LC3-II (I) and P62 (J) compared to β-actin.(L) Degradation of GFP-*Salmonella* and LC3 induction was assessed by confocal microscopy. Representative images and quantification of GFP fluorescence and LC3 accumulation as outlined in [Figure S7](#mmc1){ref-type="supplementary-material"}C. Data from six independent donors in two independent experiments. Scale bar 5 μm. Each dot represents one donor.Statistical significance was determined using Mann-Whitney U test ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.Please also see [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

We found 34 significantly differentially expressed metabolites between control and butyrate macrophages ([Figure 2](#fig2){ref-type="fig"}E). Butyrate was the most differentially expressed metabolite in butyrate macrophages confirming the validity of this approach. Butyrate macrophages also contained higher amounts of adenosine monophosphate (AMP) a known inducer of AMP kinase (AMPK) that inhibits mTOR ([@bib25]) the master regulator of autophagy ([@bib34]). In agreement with this hypothesis, AMPK Thr172 phosphorylation was significantly increased in butyrate macrophages compared to controls ([Figure 2](#fig2){ref-type="fig"}F). To test whether butyrate treatment blocked mTOR activity, we analyzed ribosomal protein S6 kinase phosphorylation by flow cytometry and immunoblot as a surrogate marker of mTOR activation. Indeed, butyrate macrophages showed a marked reduction of pS6 phosphorylation compared to control macrophages ([Figure 2](#fig2){ref-type="fig"}G). In support of the hypothesis that butyrate-induced antibacterial clearance depends on mTOR inhibition, we found that treatment with MHY1485, an mTOR activator ([Figure 2](#fig2){ref-type="fig"}H) blunted butyrate macrophage antibacterial activity ([@bib13]).

Since mTOR is a key regulator of autophagy and autophagy-related processes, we tested whether butyrate-induced antimicrobial activity was associated with bacterial-associated autophagy protein microtubule-associated protein 1 light chain 3 alpha (LC3). We tested the LC3-I to LC3-II conversion by immunoblot, LC3 flow cytometry and confocal microscopy. Immunoblot indicated that the basal and *Salmonella* infection-induced LC3-II turnover was significantly increased in butyrate macrophages ([Figure 2](#fig2){ref-type="fig"}I and 2J). In contrast to the LC3-II increase, P62 protein (SQSTM1) expression was unchanged between control and butyrate macrophages ([Figure 2](#fig2){ref-type="fig"}I and 2K), indicating an overall functional degradation of the autophagosome and normal autophagic flux. We also confirmed the increase in LC3-II turnover quantitatively by flow cytometry ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B).

Next, we investigated whether the increase in LC3-II turnover induced in butyrate macrophages is localized to intracellular *Salmonella*. To test this hypothesis, we performed confocal imaging by staining LC3 in control and butyrate macrophages infected with GFP-*Salmonella* ([Figure 2](#fig2){ref-type="fig"}L). Viable intracellular bacteria expressed a strong GFP signal. The degradation process was characterized by subsequent LC3 coating and loss of the GFP signal. Whereas in control macrophages a large proportion of *Salmonella* expressed a bright GFP signal, we found that in butyrate macrophages bacteria expressed a significantly lower GFP bright signal and a higher percentage of *Salmonella* are associated with strong LC3 coating ([Figure 2](#fig2){ref-type="fig"}L, details of the microscopy approach are described in detail in [Figure S3](#mmc1){ref-type="supplementary-material"}C). Moreover, we investigated the role of ROS generated by NADPH oxidase activity, an anti-microbial effector mechanism that typifies LC3-associated phagocytosis. In macrophages, the activity of the NADPH oxidase 2 (NOX2) enzyme complex is required for efficient recruitment of LC3 to phagosomes restricting bacterial colonization, growth in the cytosol, and elimination of invading bacteria ([@bib24]). We measured NADPH oxidase activity by luminol-chemiluminescence on macrophages stimulated with phorbol 12-myristate 13-acetate (PMA) ([Figure S3](#mmc1){ref-type="supplementary-material"}D) or after *Salmonella* infection ([Figure S3](#mmc1){ref-type="supplementary-material"}E). In both conditions, butyrate macrophages produced significantly more reactive oxygen species (ROS) as measured by a dihydrorhodamine (DHR) assay after PMA stimulation or *Salmonella* infection compared to controls ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G).

Calprotectin Mediates the Enhanced Antimicrobial Function of Butyrate Macrophages {#sec2.3}
---------------------------------------------------------------------------------

The antimicrobial effects of butyrate depended on sustained exposure during macrophage differentiation. Since butyrate has a well-known role as an HDACi, we reasoned that its effect on macrophage differentiation may be a consequence of epigenetic changes and gene expression affecting the heterogeneity of the resulting macrophage population. We therefore employed single-cell RNA-sequencing, a method that facilitates the identification and transcriptomic characterization of previously unknown cell subtypes and states ([@bib55]). We performed droplet-based single-cell RNA-seq analysis of control and butyrate macrophages from two healthy donors, retaining 5,981 cells for detailed analysis. We first performed an alignment between control and butyrate macrophages using an approach based on canonical correlation analysis (CCA) ([@bib9]). We were able to align 98.7% of the cells, confirming the existence of broadly similar cell-states in both the control and butyrate macrophage populations. We identified five major clusters of macrophages ([Figure 3](#fig3){ref-type="fig"}A) and characterized these subpopulations by identifying marker genes for each cluster that were conserved between control and butyrate macrophages (selected examples shown in [Figure 3](#fig3){ref-type="fig"}C, and [Table S1](#mmc2){ref-type="supplementary-material"}). The different clusters of macrophages were associated with distinct gene-expression profiles (cluster 0 lysosomal function; cluster 1 regulation of actin cytoskeleton and phagocytosis; cluster 4 phagosomal activity and antigen presentation; cluster 3 cell-cycle-associated genes). Cells in cluster 2 were characterized by genes associated with antimicrobial responses (*e.g., S100A8*, *S100A9)* and lysosomal functions (*LYZ*). Butyrate consistently increased the numbers of macrophages associated with the lysosomal (cluster 0) and antimicrobial phenotype (cluster 2) ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Butyrate Exposure Promotes an Antimicrobial Macrophage Phenotype(A) Single-cell RNA-seq analysis of control and butyrate treated macrophages (n = 5,836 cells) from two healthy donors. The t-SNE projection shows the five subpopulations of macrophages that were identified with a graph-based clustering algorithm (see Methods).(B) Quantitation of the proportions of control and butyrate macrophages ascribed to each of the sub-populations. Dashed lines indicate the sample pairs (shared donor identity).(C) Examples of the expression of marker genes identified (in both control and butyrate macrophages) for cells in each of the five clusters (Benjamini Hochberg \[BH\] adjusted p values \< 0.05).(D) Changes in gene expression between control and butyrate macrophages. The genes shown in the heatmap are significantly differentially expressed (BH adjusted p value \< 0.05, log~2~ fold-change \> 2) between control and butyrate macrophages in at least one of the four clusters of differentiated (non-cell-cycle associated) macrophages.(E) Selected examples of significantly enriched Gene Ontology (GO) categories among genes up (group i) or down (groups ii and iii) regulated by butyrate (BH adjusted p value \< 0.05, Fishers exact test). Please also see [Figure S4](#mmc1){ref-type="supplementary-material"} and [Tables S1--S3](#mmc1){ref-type="supplementary-material"}.

To examine the influence of butyrate, we identified genes that were differentially expressed between control and butyrate macrophages within each of the clusters of differentiated (i.e., non-cell-cycle-associated) macrophages (see Methods). We found that butyrate predominantly induced changes in gene expression across the entire population of differentiated macrophages ([Figure 3](#fig3){ref-type="fig"}D, [Table S2](#mmc3){ref-type="supplementary-material"}). Genes upregulated by butyrate were enriched for gene-ontology (GO) categories including "killing of cells of other organism" and "defense response to bacterium" ([Figure 3](#fig3){ref-type="fig"}E, [Figure S4](#mmc1){ref-type="supplementary-material"}, [Table S3](#mmc4){ref-type="supplementary-material"}). Butyrate downregulated genes associated with "cellular response to interleukin-1" and the classic complement (i.e., *C1QA*, *C1QB*, *C1QC*) activation genes in cells of cluster 2.

Overall, the single-cell data revealed a butyrate-induced antimicrobial signature characterized by the expression of *S100A8*, *S100A9*, *S10012*, *LYZ*, and *FCN1* particularly in the cluster 2 subset of differentiated macrophages ([Figure 4](#fig4){ref-type="fig"}A and S8). Because these data are based on only two individuals, we next validated the induction of *S100A8*, *S100A9*, and *S100A12* ([Figure 4](#fig4){ref-type="fig"}B) mRNA expression in butyrate macrophages compared to control macrophages by qPCR at baseline. Butyrate-induced *S100A8* and *S100A9* expression is not only observed at baseline but also in LPS stimulated cells suggesting that a short term inflammatory stimulus does not override the butyrate induced antimicrobial function ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B).Figure 4Upregulation of Calprotectin in Macrophages Differentiated in Presence of Butyrate(A) t-SNE plots of significantly (BH adjusted p value \< 0.05) butyrate-induced antimicrobial genes (*S100A8*, *S100A9*, *S100A12*, *LYZ*, and *FCN1*) at the single-cell level.(B) Gene expression of *S100A8*, *S100A9*, *S100A12* at steady state in control and butyrate macrophages.(C) Quantification of calprotectin in the supernatant by ELISA.(D) Intra-cellular expression of *S100A8* and *S100A9* protein at steady state by flow cytometry.(E) Representative immunoblot of calprotectin and β-actin at steady state from three donors.(F) Quantification of calprotectin expression at steady state.(G) Gentamicin protection assay against *Salmonella* performed on control and butyrate macrophages treated with scrambled siRNA or a mix of *S100A8* and *S100A9* siRNA.Each dot represents one donor. Statistical significance was determined using Mann-Whitney U test ^∗^p \< 0.05, ^∗∗^p \< 0.01 and ^∗∗∗^p \< 0.001.Please also see [Figure S5](#mmc1){ref-type="supplementary-material"}.

Analysis of control and butyrate macrophage supernatants by ELISA confirmed the significant increase in calprotectin protein secretion by butyrate macrophages ([Figure 4](#fig4){ref-type="fig"}C). Similarly, intracellular staining of the S100A8 and S100A9 proteins by flow cytometry shows a striking upregulation of calprotectin in macrophages after 5 days of differentiation with butyrate ([Figure 4](#fig4){ref-type="fig"}D). Quantification of calprotectin protein in the lysate of control and butyrate macrophages at steady state by immunoblot also confirmed a significant increase in butyrate macrophages ([Figures 4](#fig4){ref-type="fig"}E and 4F).

Calprotectin is a well-studied antimicrobial protein that is capable of enhancing bacterial killing via different mechanisms such as sequestration of metal ions such as zinc (Zn^2+^) and manganese (Mn^2+^) ([@bib23], [@bib30]). To confirm the functional role of *S100A8/9* in the elimination of invasive intracellular bacteria, we differentiated control and butyrate macrophages in the presence of siRNAs against *S100A8 and S100A9* before performing a gentamicin protection assay. The significant silencing of both S100A8 and S100A9 genes ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D) found in butyrate macrophages treated with *S100A8/S100A9* siRNA was associated with a significant increase of bacterial load compared to untreated or scrambled siRNA treated control and butyrate macrophages ([Figure 4](#fig4){ref-type="fig"}G). Together these results indicate that the presence of butyrate during monocyte to macrophage differentiation drives a synergistic program of antimicrobial LC3-associated host defense and production of antimicrobial peptides, which together promote cellular antimicrobial activity.

Butyrate Promotes Antimicrobial Activity in Macrophages through Its HDAC Inhibitory Function {#sec2.4}
--------------------------------------------------------------------------------------------

Since butyrate can signal via G protein--coupled receptors (GPCRs) ([@bib7]), we studied the role of GPCRs in butyrate-induced bacterial clearance. We found that mRNA expression of the known butyrate receptors *FFAR2*, *FFAR3*, and *HACR2* genes were more highly expressed in myeloid populations than lymphoid and dendritic cell populations ([Figures 5](#fig5){ref-type="fig"}A--5C). However, macrophages differentiated in the presence of both butyrate and the GPCR inhibitor pertussis toxin (PT) still exhibited enhanced anti-bacterial activity ([Figure 5](#fig5){ref-type="fig"}D) suggesting that GPCRs are not required for butyrate induced antimicrobial functions.Figure 5Butyrate Promotes Antimicrobial Activity in Macrophages via HDAC Inhibitory Function(A--C) Gene expression of *hcar2* (A), *ffar2* (B), and *ffar3* (C) on flow cytometry sorted CD19^+^ B, CD8^+^ T, naive CD4^+^ T, memory CD4^+^ T, CD56^+^ CD3^−^ NK cells, CD14^+^ monocytes, CD141^+^ DCs, and CD1c^+^ DCs from the blood of healthy donors. Each dot represents one donor.(D) Gentamicin protection assay on control and butyrate macrophages, or butyrate macrophages differentiated in the presence of butyrate with pertussis toxin (PT).(E) Protein expression of acetyled histone 3 (Ac-H3) and acetyled histone 4 (Ac-H4) in control and butyrate macrophages (data from 2 individual donors per condition).(F and G) Intra-cellular expression of tri-methylated lysine27 on histone 3 (3MeH3K27) (F) and acetylated lysine 27 on histone 3 (AcH3K27) (G) protein on control and butyrate macrophages by flow cytometry.(H, J, L, and N) Gentamicin protection assay on control macrophages, butyrate macrophages, and macrophages differentiated in the presence of valproate, phenylbutyrate (H), SAHA (J), TMP195, and tubacin (L), SBHA, 1-naphthohydroxamic acid (NA), or RGFP966 (N).(I, K, M, and O) Gene expression of *S100A8* in control macrophages, butyrate macrophages, and macrophages differentiated in the presence of valproate, phenylbutyrate (I), SAHA (K), TMP195, and tubacin (M), SBHA, 1-naphthohydroxamic acid (NA), or RGFP966 (O).(P) Gentamicin protection assay in control and butyrate macrophages with and without HDAC3 siRNA-mediated gene silencing.(Q) Extracellular acidification rate in control and butyrate macrophages, as well as in RGFP966 and TMP195 treated macrophages. Data represent the mean of three biological replicates.For the gentamicin protection assay, the percentage of CFU (of control) was calculated from mean value for control group.Each dot represents one independent donor. For pairwise comparison Mann-Whitney U test was performed and for multiple group comparisons a one-way ANOVA (Kruskal-Wallis test) was performed. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.Please also see [Figure S5](#mmc1){ref-type="supplementary-material"}E.

We next tested the role of the histone deacetylase (HDAC) inhibitory function of butyrate in enhancing antimicrobial function ([@bib42]). HDACs remove acetyl groups on specific lysine residues from histones and non-histone proteins regulating gene expression by modulating chromatin structure. We tested the ability of butyrate to inhibit HDAC activity in macrophages, using histone H3 and H4 acetylation as an indirect readout. Butyrate macrophages displayed a higher amount of acetylated H3 and H4 compared to controls ([Figure 5](#fig5){ref-type="fig"}E). Furthermore, butyrate macrophages showed a significant decrease of the tri-methylation of lysine 27 on histone 3 (3MeH3K27), associated with chromatin repression ([Figure 5](#fig5){ref-type="fig"}F), as well as increased acetylation of lysine 27 on histone 3 (AcH3K27), which is associated with more open chromatin ([Figure 5](#fig5){ref-type="fig"}G). In support of these findings, treatment of macrophages with pan-HDAC inhibitors such as valproate, phenyl-butyrate, and veronistat (SAHA) increased their antimicrobial activity ([Figure 5](#fig5){ref-type="fig"}H and 5J) and increased expression of *S100A8* mRNA ([Figure 5](#fig5){ref-type="fig"}I and 5K).

We next investigated the specificity of butyrate-mediated HDAC inhibition in macrophages. HDACs are divided into 2 main classes: class I and class II (subdivided into IIa and IIb) ([@bib21]). We initially treated macrophages with TMP195, an inhibitor of HDAC class IIa ([@bib15]) that has been used to activate tumor-associated macrophages ([@bib20]) and with tubacin that targets HDAC class IIb. However, neither macrophages differentiated in the presence of TMP195 nor tubacin showed changes in bactericidal function ([Figure 5](#fig5){ref-type="fig"}L) or upregulation of *S100A8* mRNA ([Figure 5](#fig5){ref-type="fig"}M) suggesting that butyrate does not act via inhibition of class II HDAC. Next we treated macrophages with several inhibitors that target class I HDACs: valproate (class I HDACi and reduces protein expression of HDAC2), SBHA (targeting HDAC1 and 3), 1-naphthohydroxamic Acid (NA; targeting HDAC8, 1, and 6), and RGFP966 (a HDAC3-specific inhibitor) ([@bib27]). We found that macrophages differentiated with valproate and SBHA but not NA showed a significant reduction of CFU compared to control macrophages ([Figure 5](#fig5){ref-type="fig"}N). Similarly, the HDAC3 inhibitor RGFP966 induced elevated bacterial clearance ([Figure 5](#fig5){ref-type="fig"}N) and increased *S100A8* mRNA expression ([Figure 5](#fig5){ref-type="fig"}O). Silencing of HDAC3 with siRNA resulted in significantly increased *Salmonella* clearance at baseline in control macrophages. Importantly, butyrate failed to enhance bacterial killing in macrophages with HDAC3 silencing ([Figure 5](#fig5){ref-type="fig"}P and Figure S5E). Together these results show that inhibition of HDAC3 is sufficient to induce the differentiation of macrophages with bactericidal functions and that butyrate's anti-microbial effects on macrophages are dependent on HDAC3. Macrophages differentiated with the HDAC3 inhibitor RGFP966 but not TMP195 also showed reduced glycolysis similar to butyrate macrophages indicating inhibition of HDAC3 is upstream of both metabolic changes and anti-microbial responses in macrophages ([Figure 5](#fig5){ref-type="fig"}Q).

Butyrate Treatment Promotes Antibacterial Activity in Intestinal Macrophages and Restricts Bacterial Translocation *In Vivo* {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------

To test whether the effects of butyrate on macrophage differentiation are relevant *in vivo*, we treated C57BL/6 mice with a daily oral dose of butyrate or water for 7 days. At day 7, we sorted colonic macrophages by flow cytometry and performed an *ex vivo* gentamicin protection assay. In line with our *in vitro* findings, colonic macrophages from butyrate treated-mice exhibited higher antimicrobial activity compared to controls ([Figure 6](#fig6){ref-type="fig"}A). To confirm that the increase in bacterial killing is specific to colonic macrophages, we induced the differentiation of bone marrow (BM) progenitors from butyrate-treated or from untreated mice in the presence of M-CSF to determine whether macrophages derived from the BM of butyrate-treated animals displayed increased antimicrobial activity. Macrophages differentiated from butyrate-treated mice did not show any improvement in antibacterial function compared to macrophages differentiated in the presence of butyrate ([Figure 6](#fig6){ref-type="fig"}B) indicating butyrate functions through local effects on intestinal macrophages.Figure 6Induction of Antimicrobial Activity by Butyrate in Macrophages *In Vivo*(A) WT mice received sodium butyrate in drinking water (150 mM final concentration) or PBS control for 7 days. At day 7, colonic segments were digested, macrophages were isolated by flow cytometry sorting and a gentamicin protection assay was performed. Each dot represents macrophages pooled from ten mice. Four independent experiments are shown.(B) Mouse bone marrow progenitor cells from mice gavaged with sodium butyrate or with PBS were differentiated into macrophages in the presence of M-CSF or with M-CSF with butyrate as a positive control. A gentamycin assay was performed at day 7 of differentiation.(C and D) Mice received butyrate or PBS 5 days prior to oral infection with *Salmonella typhymurium def aroA* (1 × 10^9^ bacteria/mouse). 2 days post-infection bacterial dissemination was assessed in MLN, spleen, liver (C), and caecum (D). Each dot represents a mouse.(E) Colitis score of control and butyrate-treated mice either uninfected or infected with *Salmonella*.(F) Representative H&E stained colon sections from control and butyrate-treated mice either uninfected or infected with *Salmonella* (original magnification 100x).(G and H) Mice were treated with 150 mM sodium butyrate or with PBS 3 days prior and every other day after oral infection with *Citrobacter rodentium* (1 × 10^9^ bacteria/mouse). Mice were weighed daily. Lines represents mean of 3 mice (G). At day 7 post infection bacterial dissemination was assessed in the spleen and in the liver (H). Each dot represents a mouse. Statistical significance was determined using Mann-Whitney U test ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001.Please also see [Figure S6](#mmc1){ref-type="supplementary-material"}.

We next investigated whether mice treated orally with butyrate showed a reduction in dissemination of bacteria to peripheral organs after infection. Mice were treated orally for 7 days with butyrate prior to oral infection with *Salmonella* or *C. rodentium*. Two days after *Salmonella* infection, bacterial dissemination was quantified. Butyrate-treated mice showed a significant reduction of bacterial dissemination in the mesenteric lymph node (MLN), spleen, and liver compared to untreated mice ([Figure 6](#fig6){ref-type="fig"}C), though *Salmonella* load in the caecal contents of both groups of mice was not different ([Figure 6](#fig6){ref-type="fig"}D). Salmonella infection was associated with a mild inflammatory response in the colon, which was reduced in butyrate treated mice ([Figures 6](#fig6){ref-type="fig"}E and 6F). This effect was not associated with an increase in the frequency of CD4^+^Foxp3^+^ regulatory T cells ([Figure S6](#mmc1){ref-type="supplementary-material"}).

Similar results were observed after infection with *C. rodentium*. While both groups had similar weight curves during infection ([Figure 6](#fig6){ref-type="fig"}G), butyrate-treated mice displayed a marked reduction in the dissemination of *C. rodentium* to the liver and spleen ([Figure 6](#fig6){ref-type="fig"}H) indicating that butyrate promotes anti-microbial defense *in vivo*.

These results indicate that oral butyrate supplementation promotes the differentiation of intestinal macrophages that possess strong antimicrobial activity and that this reduces the dissemination of pathogenic bacteria.

Discussion {#sec3}
==========

The intestinal immune system is highly adapted to provide host defense in the face of pathogens while retaining a mutualistic response with commensal bacterial. Bacterial fermentation products SCFA are major mediators of host-microbe cross talk in the intestine, controlling the development and maintenance of indigenous bacterial communities on the one hand and differentiation and maturation of intestinal tissue and immune cells on the other ([@bib42]). Here we have identified a role for butyrate as a differentiation factor for monocyte-derived macrophages that enhances cell-intrinsic antimicrobial functions. We have shown that butyrate acted via its HDAC3 inhibitory function to alter metabolism and induce production of anti-microbial peptides leading to enhanced bactericidal function *in vitro* and *in vivo*.

Butyrate caused a profound metabolic and immunologic alteration in macrophages that is in many aspects opposite to the well-known pro-inflammatory LPS stimulation or "trained immunity" seen in pro-inflammatory M1 macrophages. LPS treated macrophages show increased glycolysis, inhibition of AMPK, increase of mTOR signaling, as well as reduced carbohydrate kinase-like protein (CARKL) mRNA that flux into the pentose phosphate pathway ([@bib31]). By contrast, macrophages differentiated in the presence of butyrate show reduced glycolysis, higher amounts of AMP and increased AMPK phosphorylation at Thr172, a residue that is critical for enzyme activity ([@bib22]). Butyrate macrophages also show reduced S6 phosphorylation, a surrogate marker for inhibition of mTOR. Reductions in mTOR, which is a known positive regulator of glycolytic enzymes such as hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, and lactate dehydrogenase-B ([@bib49]) may explain the reduced glycolysis observed in butyrate macrophages. In addition, butyrate treated macrophages show increased amounts of ribulose 5-phosphate and reduced intracellular glucose (despite normal glucose uptake) suggesting an increased flux toward the pentose phosphate pathway. An increased flux toward the pentose phosphate pathway could contribute to the generation of NADPH, which may fuel the increased NADPH-oxidase-dependent ROS observed in butyrate macrophages both at baseline and also after *Salmonella* infection. Consistent with previous data that increased AMP kinase activity inhibits mTOR signaling and induces autophagy ([@bib31], [@bib44]), we found increased LC3 and increased bacterial clearance as a marker of effective autophagy in butyrate differentiated macrophages ([@bib34]). Our results suggest an LC3-associated process since butyrate macrophages express high amounts of lipidated LC3-II protein detected by immunoblot, flow cytometry, and microscopy. However, we cannot differentiate whether the effects of butyrate are linked to canonical autophagy or non-canonical LC3-associated phagocytosis pathways ([@bib38]).

Single-cell RNA-sequencing identified five clusters of gene expression among human monocyte-derived macrophages with enrichment of distinct cellular processes reiterating the emerging concept of phenotypic and functional heterogeneity. Addition of butyrate increased expression of a number of anti-bacterial and host defense genes supporting the marked increase in bacterial killing in butyrate macrophages at the population level. However, a butyrate-induced antimicrobial signature involving the expression of *S100A8*, *S100A9*, *S10012*, *LYZ*, and *FCN1* was particularly pronounced in a subset of differentiated macrophages (cluster 2). The modulation of metabolic regulation toward LC3-associated processes in conjunction with induction of multiple antimicrobial genes within those cells provides the machinery for intracellular bacterial segregation and effector mechanisms for killing. Calprotectin (a heterodimer of S100A8 and S100A9) mRNA and protein was detected in butyrate macrophages. Gene silencing of calprotectin ablated the increased anti-bacterial properties of butyrate macrophages, illustrating the functional importance of this anti-microbial peptide. Calprotectin can inhibit the growth of intracellular pathogens by a number of mechanisms including chelation of bivalent cations ([@bib61]), activation of NADPH oxidase ([@bib33]), or induction of lipidated LC3-II ([@bib59]).

We have shown that HDAC3 inhibition by butyrate (or the specific HDAC3i RGFP966) drove the differentiation of macrophages, altered their metabolism, and enhanced gene expression of antimicrobial peptides uncoupled from increased inflammatory cytokine production. Butyrate has been shown to act as an HDACi to inhibit acute LPS stimulated inflammatory cytokine production by murine macrophages *in vitro* ([@bib11]). In that setting HDAC3 deficiency or inhibition has anti-inflammatory function ([@bib12], [@bib35]). *Lyz2-cre*^+^, *Hdac3*^f/f^ macrophages also polarize more strongly toward an M2 phenotype when stimulated with IL-4 ([@bib39]). However, that function is context dependent and requires IL-4 signaling. Our findings complement and extend previous studies by showing that butyrate through its HDAC3i function can also induce the differentiation of a specialized macrophage anti-microbial state in the absence of changes in inflammatory cytokine production. Together these studies support a model in which butyrate imprints a non-inflammatory and antimicrobial program in macrophages that promotes intestinal homeostasis. This is consistent with the concept that butyrate-producing commensal bacteria shape host microbial crosstalk to promote a stable relationship, avoiding the disruptive effects of inflammation on the ecosystem. This is an important mechanism, since genetic defects in bacterial handling and reduction in butyrate producing bacteria have been linked to IBD ([@bib6], [@bib10], [@bib17]). This also fits with the observation that human intestinal macrophages showed reduced inflammatory potential compared to peripheral blood monocytes ([@bib8]). Our results show that mice pre-treated with butyrate exhibit a reduction of systemic dissemination when orally infected with *C. rodentium* or *Salmonella*. Although we cannot exclude that in the *in vivo* setting butyrate promotes antimicrobial barrier function via several mechanisms, macrophages sorted from the colon of butyrate-fed mice display an increase in bactericidal function and an upregulation of *S100A8* mRNA suggesting that these cells contribute to antimicrobial homeostasis.

Epidemiological studies suggest that early life exposure to antibiotics is a risk factor and a high-fiber diet (associated with increased luminal butyrate concentrations) is a protective factor in IBD ([@bib1], [@bib14]). In a model system, broad spectrum antibiotics causes butyrate depletion and butyrate-responsive macrophage and T cell dysfunction ([@bib43]). Restoring antimicrobial function via butyrate in intestinal macrophages may therefore be a universal mechanism to prevent or treat IBD. It is feasible to pharmacologically increase butyrate concentrations via enema *in vivo* in portal vein blood to 92.2 μmol/L ([@bib52]). Although it is not yet clear whether enemas containing butyrate or a cocktail of SCFAs can ameliorate intestinal inflammation ([@bib14]), treatments that harness butyrate effector mechanisms might have the potential to prevent IBD or reduce relapse activity. Our findings suggest clear differences between the anti-tumor inflammatory macrophages induced by the class II HDACi TMP195 and antimicrobial macrophages induced by HDAC3 targeting inhibitors suggesting a concept of differential imprinting of macrophage function via selective HDAC inhibition. It remains to be determined whether selective HDAC3 inhibitors would have an advantage beyond their natural counterpart butyrate. Indeed, HDAC3 inhibition might induce complex effects on other cell types such as those present in the epithelium ([@bib60]).

In conclusion, our results demonstrate that butyrate directs the differentiation of homeostatic macrophages that possess strong antimicrobial activity and play an important role in preventing the dissemination of bacteria beyond the intestinal barrier. Butyrate educates developing macrophages via HDAC3 inhibition by regulating their metabolic and transcriptional program. This has implications for prevention and therapy of disorders that are associated with intestinal inflammation, as well as systemic infection.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-CD45RO-APC Cy7/biotin (Clone UCHL1)BioLegenedCatalog\# 304228; RRID:[AB_10895897](nif-antibody:AB_10895897){#interref85}CD45RA PE Cy7/biotin (Clone HI100)BioLegenedCatalog\# 304125; RRID:[AB_10709440](nif-antibody:AB_10709440){#interref90}CD8-V500/biotin (Clone RPA-T8)BiosciencesCatalog\# 560775; RRID:[AB_1937333](nif-antibody:AB_1937333){#interref95}CD19- BV650/biotin (Clone HIB19)BioLegendCatalog\# 302238; RRID:[AB_2562097](nif-antibody:AB_2562097){#interref100}7AADBioLegend420403Annexin V-BV510BioLegend640937Anti-GLUT1 (Clone FAB1418P)RnD SystemsCatalog\# FAB1418P; RRID:[AB_2191040](nif-antibody:AB_2191040){#interref105}Anti-CD14 (Clone M5E2)BioLegendCatalog\# 301804; RRID:[AB_314186](nif-antibody:AB_314186){#interref110}Anti-CD11c (Clone B-Ly6)BD BiosciencesCatalog\# 657713; RRID:[AB_2760137](nif-antibody:AB_2760137){#interref115}Anti-HLA-DR (Clone G46-6)BD BiosciencesCatalog\# 561224; RRID:[AB_10563765](nif-antibody:AB_10563765){#interref120}Anti-Foxp3-PE-eFluor610 (Clone FJK-16s)eBioscienceCatalog\# 61-5773-80; RRID:[AB_2574623](nif-antibody:AB_2574623){#interref125}Anti-CD4-BV785 (Clone RM4-5)BioLegendCatalog\# 100552; RRID:[AB_2563053](nif-antibody:AB_2563053){#interref130}Anti-CD45-BV650 (Clone 30-F11)BioLegendCatalog\# 103151; RRID:[AB_2565884](nif-antibody:AB_2565884){#interref135}Anti-CD3-PECy7 (Clone 145-2C11)BioLegendCatalog\# 100320; RRID:[AB_312685](nif-antibody:AB_312685){#interref140}fixable viability dyeeBioscienceCatalog\# 65-0865-14Anti-S100A8 (Clone CF-145)eBioscienceCatalog\# 50-9745-42; RRID:[AB_2574354](nif-antibody:AB_2574354){#interref145}Anti-S100A9 (Clone MRP-14)BioLegendCatalog\# 350706; RRID:[AB_2564008](nif-antibody:AB_2564008){#interref150}Anti-phosphor-S6 (ser235, ser236) (Clone cupk43k)eBioscienceCatalog\# 12-9007-42; RRID:[AB_2572667](nif-antibody:AB_2572667){#interref155}Anti-acetyl-histone H3 (lys27) (Clone D5E4)New England biolabsCatalog\# 8173; RRID:[AB_10949503](nif-antibody:AB_10949503){#interref160}Anti-tri-methyl-histone H3 (lys27) (Clone C36B11)New England biolabsCatalog\# 9733; RRID:[AB_2616029](nif-antibody:AB_2616029){#interref165}Anti-LC3B (Clone D11)Cell signalingCatalog\# 3868; RRID:[AB_2137707](nif-antibody:AB_2137707){#interref170}Anti-β-actin (Clone 13E5)Cell signalingCatalog\# 5125; RRID:[AB_1903890](nif-antibody:AB_1903890){#interref175}Anti-phosphor-S6 ribosomal protein (Ser235/236) (Clone D57.2.2E)Cell signalingCatalog\# 4858; RRID:[AB_916156](nif-antibody:AB_916156){#interref180}Anti-S100A8 (Clone EPR3554)AbcamCatalog\# ab92331; RRID:[AB_2050283](nif-antibody:AB_2050283){#interref185}Anti-acetylated-H3 (Clone ab47915)AbcamCatalog\# ab47915; RRID:[AB_873860](nif-antibody:AB_873860){#interref190}Anti-acetylated-H4 (Clone EPR16606)AbcamCatalog\# ab177790; RRID:[AB_2732882](nif-antibody:AB_2732882){#interref195}Anti-P62 lck (Clone 2/P62 LCK Ligand)BD bioscienceCatalog\# 610833; RRID:[AB_398152](nif-antibody:AB_398152){#interref200}HRP-conjugated secondary antibody (anti-rabbit)Cell signalingCatalog\# 7074SHRP-conjugated secondary antibody (anti-rabbit)Cell signalingCatalog\# 7076S**Bacterial strains***Salmonella enterica* serovar TyphimuriumD. Holden (Imperial College, University of London, UK)NCTC 12023CD-associated adherent invasive *Escherichia coli* (*AIEC*)Arlette Darfeuille-Michaud lab FranceLF82.30*Staphylococcus aureus*National collection of type culturesNCTC 6571*Citrobacter. rodentium*Gad Frankel in Imperial College LondonICC169*Salmonella* (mouse)Gordon Dougan lab, Cambridge universitySL1344**Chemicals**Human M-CSFPreprotech300-25-100Sodium ButyrateSigma-Aldrich303410-100GSodium AcetateSigma-AldrichS2889-250GSodium PropionateSigma-AldrichP1880Sodium ValproateSigma-AldrichS0930000Sodium PhenylbutyrateSigma-AldrichSML0309RGFP966Sigma-AldrichSML1652SAHASigma-AldrichSML0061SBHASigma-Aldrich390585TubacinSigma-AldrichSML00651-naphthohydroxamicSigma-AldrichSML00783-MASigma-AldrichM9281-100MGMHY1485Sigma-AldrichSML0810TMP195Cellagen TechnologyC8619-2GentamicinSigma-AldrichG1397-10MLSeahorse XFe96 FluxPakAgilent102601-100Seahorse XF base medium, sterile, 1 L, 2/pkAgilent102353-100Feotal calf serumSigma-aldrichF2442-6X500MLPenicillin/streptomycinSigma-aldrichP4333-100MLHEPESSigma-aldrich83264-100ML-FTritonSigma-aldrichT-8787-100ML2NBDGSigma-aldrich72987-1MG**Commercial assays**Phagocytosis kit (Escherichia coli (K-12 strain) BioParticles™, Alexa Fluor™ 488 conjugate)ThermofisherE-13231 and CD14 MicroBeads, human; Source Miltenyi Biotec 130-050-201Seahorse XF glycolysis stress test kit -- 96x wellsAgilent103020-100Seahorse XF mito stress test kit -- 96x wellsAgilent103015-100AMPK alpha-1,2 (Phospho) \[pT172\] Human ELISA KitThermofisherKHO0651**Softwares**Cell Ranger (Version 2.0.2)10X Genomics<https://support.10xgenomics.com>R (Version 3.4.2)The Comprehensive\
R Archive Network (CRAN)<https://cran.r-project.org>/RStudio server (Version 1.1.383)RStudio, Inc.<https://www.rstudio.com/>Pipelines for analyzing data generated with the 10x Genomics platformSansom Lab<https://github.com/sansomlab/tenx>Seurat R package (Version 2.1)CRAN<https://CRAN.R-project.org/package=Seurat>DESeq2 (version 1.18.1)Bioconductor<http://bioconductor.org/packages/DESeq2/>FlowJoFlowJo<https://www.flowjo.com/>ImageJImageJ<https://imagej.nih.gov/ij/>PrismPrism - [graphpad.com](http://graphpad.com){#intref0050}<https://www.graphpad.com/scientific-software/prism/>**Others**Seahorse XFe96 FluxPakAgilent102601-100**Deposited data**Single cell dataGene Expression Omnibus (GEO)([GSE111049](ncbi-geo:GSE111049){#interref205})

Human monocytes, differentiation and cell culture {#sec4.2}
-------------------------------------------------

Human monocytes were isolated from leukocyte cones of healthy blood donors. Peripheral blood mononuclear cells (PBMC) were obtained by ficoll gradient. Monocyte-derived macrophages were generated using adherence method selection and M-CSF differentiation. Whole PBMC (50x10^6^) were plated in RPMI-1640 medium for 90 min. After 2 washes with PBS, adherent monocytes were differentiated into macrophages over a 5 day period in presence of 100 ng/mL M-CSF in RPMI supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich), 100 U/mL penicillin, 100 μg/mL streptomycin, 30 mM HEPES, and 0.05 mM β-mercaptoethanol.

Reagents {#sec4.3}
--------

All chemicals Butyrate (1mM), Acetate (1mM), Propionate (1mM), SAHA (1μM), SBHA (20μM), TMP195 (10 μM), RGFP966 (20 μM), 1-NA (10 μM), tubacin (1μM), 1-naphthohydroxamic acid, bafilomycin A1, 3-MA, MHY1485) were purchased from Sigma-Aldrich, unless specified otherwise. TMP195 was acquired from Cellagen technology and Cayman chemical respectively. Recombinant human and murine M-CSF were purchased from PeproTech.

Bacterial strains and gentamicin protection assay {#sec4.4}
-------------------------------------------------

Gentamicin protection assay was performed with the following strains: *Salmonella enterica* serovar Typhimurium (*Salmonella*)-expressing green-fluorescent protein (GFP) (NCTC 12023), CD-associated adherent invasive *Escherichia coli* (*AIEC*) reference strain LF82.30, *Staphylococcus aureus* (NCTC 6571). All strains were used at an MOI of 10 unless specified otherwise. For the gentamicin protection assay, macrophages were infected for 1h with *Salmonella* or *AIEC* or *S. aureus* or *C. rodentium* followed by gentamicin treatment for 2h. Cells were then lysed in 1% triton buffer and the lysate was plated on agar plates. Results are presented as absolute CFU count or % of mean control.

Seahorse assay {#sec4.5}
--------------

Extra cellular acidification rate (ECAR) of the control and butyrate treated Macrophages was quantified by using a XF 96 extracellular flux analyzer (Seahorse Bioscience). 100,000 macrophages / well was plated in Seahorse base media was supplemented with 1% FCS, 1mM glutamine and 2mM sodium pyruvate. Plate were incubated in a Co~2~ free incubator at 37°C for 1 h and later transferred to Seahorse machine for ECAR quantification. The assay was performed on 8 donors (biological replicates) with 5-8 technical replicates per donor. Similarly, for the mito-stress test, oxygen consumption rate (OCR) was quantified using a XF 96 extracellular flux analyzer (Seahorse Bioscience) as per the manufactures protocol. Base media for mito-stress was supplemented with 1% FCS, 1mM glutamine, 2mM sodium pyruvate and 10mM glucose.

Metabolomics analysis by LC-MS {#sec4.6}
------------------------------

### Metabolite extraction from cells {#sec4.6.1}

Metabolites were extracted from approximately 1x10^6^ cells (grown in cell culture dishes) by addition of 500 μL of ice cold 80% aqueous methanol. The supernatants were combined and filtered using a 3 kD ultrafilter (Millipore), dried in a SpeedVac and subsequently stored at −80°C. On the day of analysis, the dried extracts were re-constituted in 60 μL of ice cold 80% aqueous methanol. A quality control (QC) sample was made by combining 5 μL of each sample. This was injected at the start of the sequence and subsequently every 10 samples throughout the LC-MS/MS analyses.

### LC-MS/MS analysis {#sec4.6.2}

Each sample was analyzed using two different LC-MS/MS methods utilizing two separate chromatographic systems. The first method used ion-chromatography coupled directly to Q-exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer (IC-MS) (Thermo Scientific San Jose, CA). The second method utilized reversed-phase ultra-high performance chromatography (UHPLC) coupled directly to the same Q-exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Ultimate 3000, Thermo Scientific, San Jose, CA). Both methods have been published previously and further details can be found in ([@bib18], [@bib41]).

### Data processing {#sec4.6.3}

Raw data files were processed using ProgenesisQI (Waters, Elstree, UK). This involved alignment of retention times, peak picking by identification of the presence of natural abundance isotope peaks, characterizing multiple adduct forms and identification of metabolites using our in-house database of authentic standards. Retention times, accurate mass values, relative isotope abundances and fragmentation patterns were compared between authentic standards and the samples measured. Identifications were accepted only when the following criteria were met: \< 5ppm differences between measured and theoretical mass (based on chemical formula), \< 30 s differences between authentic standard and analyte retention times, isotope peak abundance measurements for analytes were \> 90% matched to the theoretical value generated from the chemical formula. Where measured, fragmentation patterns were matched to least the base peak and two additional peak matches in the MS/MS spectrum to within 12ppm. The top 10 data directed fragmentation method was not always able to provide fragment ions for all ions measured in the MS 1 spectrum.

### Data analysis {#sec4.6.4}

Principal Component Analysis (PCA) was performed using Progenesis QI. Fold change, % CV and p values were generated automatically in progenesis QI and verified manually using a normalized abundance output and Excel. Heatmaps were generated manually using the verified fold-change output. p values were generated using ANOVA (independent conditions). Statistical differences were annotated according to the scale ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Unsupervised clustering analysis was performed using the ClustVis web tool (<https://biit.cs.ut.ee/clustvis/>).

AMPK ELISA {#sec4.7}
----------

Monocytes were differentiated in the presence of M-CSF and butyrate or left untreated for 5 days. For quantification of pAMPK phosphorylation 100,000 macrophages were plated in flat bottom plates and AMPK quantification was performed at baseline after cell lysis as per the manufactures protocol (KHO0651; Thermo scientific).

Annexin V and 7AAD staining {#sec4.8}
---------------------------

For the Annexin V and 7AAD staining, 250,000 cells were harvested after 5 days of differentiation. In the case of *Salmonella* infection, cells were infected at an MOI of 10 for 1 h prior to staining. Annexin V and 7AAD staining was performed as per the manufactures protocol.

Measurement of reactive oxygen species {#sec4.9}
--------------------------------------

Production of reactive oxygen species by macrophages was evaluated with the chemiluminescence probe L-012 (100 μM, Wako laboratories, Japan) in opaque white 96-well plates. Cells were activated with 100ng/mL of PMA or infected with *Salmonella* (MOI 10) for 30 min. The luminescence was recorded every 2 min for 90 min with a plate reader (FLUOstar OPTIMA, BMG labtech). For the flow cytometric dihydrorhodamine (DHR) assay, macrophages were treated with DHR (2.5 μg/mL) and stimulated with/without 100 ng/mL PMA and analyzed by flow cytometry.

Confocal microscopy {#sec4.10}
-------------------

Quantification of GFP positive bacteria and *Salmonella*-associated LC3 was performed by confocal microscopy. Control and butyrate treated macrophages (1x10^5^) were seeded in 8-well chamber slides (Sarstedt) and were infected with GFP *Salmonella* Typhimurium at an MOI of 20 for 1 h. Cells were then treated for an additional 1 h with gentamicin (100μg/ml) to kill extracelluar *Salmonella*. Cells were fixed with 2% paraformaldehyde and then permeabilized with 0.1% Triton X-100 for 10 min. Fixed and permeabilized cells were stained with anti-LC3 (clone PM036, MBL) and secondary antibodies (Alexa Fluor 568 goat anti-rabbit IgG, Life technologies). Cellular and bacterial DNA was stained with DAPI. Finally, images of macrophages were acquired as z stacks of multiple sections collected at 0.5 μm intervals at 63x magnification with a Zeiss 510 or 780 inverted confocal microscope (ZEN2009 or ZEN2011 software). A minimum of 100 infected cells were evaluated and quantified with ImageJ software. For the microscopy quantification of *Salmonella* degradation, bacteria were classified into GFP^bright^ LC3^negative/dim^ (i.e., early stage *Salmonella* infection with intact GFP signal) and GFPdimLC3bright (LC3 coated *Salmonella* with quenched or degraded GFP signal). In addition there are intermediate stages of GFP^dim^LC3^dim^ (Intermediate phase) and GFP^negative^LC3^negative^ *Salmonella* (end stage degradation with bacterial DNA remnant). DAPI stain was used to identify intracellular bacteria. The microscopy acquisition setting was used to identify GFP^bright^ and LC3^bright^ bacteria whereas the enhanced brightness setting of each image was used to confirm the bacterial DNA content and to identify intermediate stages.

Flow cytometry {#sec4.11}
--------------

Phenotyping and characterization of activation markers of human monocytes-derived macrophages were performed by flow cytometry. Cells were harvested, washed and counted before being incubated for 20 min at 4°C in PBS with 5% BSA containing the following surface antibodies: CD14 (clone M5E2) (Biolegend), CD11c (clone B-Ly6), HLA-DR (G46-6) (BD Biosciences) and fixable viability dye (eBioscience). Following surface staining, cells were fixed and permeabilized with the Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer's instructions. Cells were intra-cellularly stained with S100A8 (clone CF-145, eBioscience), S100A9 (clone MRP1H9, Biolegend), phospho-S6 (ser235, ser236) (clone cupk43k, eBioscience), acetyl-histone H3 (lys27) (clone D5E4) (New England biolabs) and tri-methyl-histone H3 (lys27) (clone C36B11) (New England biolabs). LC3-turnover was assessed by flow cytometry with the Autophagy Detection Reagent according to manufacturer's instructions (Merck Millipore). GLUT1 receptor expression was quantified by flow cytometry (n = 4 healthy donors). 250,000 macrophages were surface stained in the flow cytometry staining buffer for 20 min on ice. Glucose uptake was quantified using 2-NBDG, a fluorescent glucose analog. Cells were incubated with 10μM 2-NBDG in RPMI + 10% FCS media at 37°C. All cells were acquired on a LSRII or a Fortessa (BD Biosciences). All analysis was performed using FlowJo software (Tree Star, Ashland, OR).

CD45^+^CD3^+^CD4^+^FOXP3^+^ T cells quantification {#sec4.12}
--------------------------------------------------

Cells were isolated as described in Methods (Isolation of mouse colonic macrophages). Staining was performed on uninfected mice or 48 h after *Salmonella* infection. Butyrate-treated mice received butyrate 5 days before and during infection in the drinking water. Lamina propria and spleen CD45^+^CD3^+^CD4^+^FOXP3^+^ T cells were analysed by flow cytometry.

Analysis of single-cell transcriptomics data {#sec4.13}
--------------------------------------------

Single-cell RNA-sequencing libraries were generated using the 10x Genomics Single Cell 3′ Solution (version 2) and subjected to Illumina sequencing (HiSeq 4000). The computational workflow used to analyze the 10x Genomics data is available at <https://github.com/sansomlab/tenx>. Briefly, reads were aligned using 10x Genomics Cell Ranger pipeline (version 2.0.2) and human reference sequences (version 1.2.0). To circumvent known index-hopping issues with the HiSeq 4000 platform ([@bib45]), cell barcodes common to more than one sample were removed from the aggregated count matrix. UMI counts were randomly down-sampled so as to normalize the median number of per-cell counts between the samples. Data were then processed using the Seurat CRAN package (version 2.2.0). Cells with \> 20% mitochondrial reads or fewer than 500 genes were excluded from the analysis. Per-cell counts were normalized, scaled and the effects of total UMI count, percentage of mitochondrial UMI count, and donor (within the control and butyrate conditions) regressed out. Cells from the two conditions were then aligned using an approach based on canonical correlation analysis ([@bib9]). We retained the first 13 CCA components, and discarded cells for which the variance explained by CCA was \< 2-fold (i.e., ratio \< 0.5) of that observed with PCA. Clusters of cells were identified using the FindClusters function of the Seurat package (original Louvain algorithm, resolution = 0.3) and visualized by t-Distributed Stochastic Neighbor Embedding (t-SNE) projection (perplexity = 20, [Figure 3](#fig3){ref-type="fig"}A) ([@bib53]). For each cluster of cells, markers were identified using the MAST test ([@bib16]) as implemented in the Seurat package (default parameters; [Table S1](#mmc2){ref-type="supplementary-material"}). Conserved cluster markers ([Figure 3](#fig3){ref-type="fig"}C) were identified as those achieving a maximum BH adjusted P value of \< 0.05 when tested within each of the samples separately. Gene set enrichment analysis ([Figure 3](#fig3){ref-type="fig"}E) was performed using Fisher's Exact Test (FET), Biological Process gene sets obtained from Gene Ontology (GO) databases ([@bib4], [@bib29], [@bib36], [@bib48]), and a gene universe that comprised of genes expressed in the differentiated Macrophages (n = 11,218). To identify genes differentially expressed between control and butyrate macrophages, we first summed the counts for each samples' cells within each of the clusters. The DESeq2 package ([@bib37]) was then used to model the replicated, paired design and to perform a test for differential gene expression between control and butyrate macrophages within each of the clusters. The accession number for the single cell sequencing reported in this paper is Gene Expression Omnibus: [GSE111049](ncbi-geo:GSE111049){#intref0070}.

Quantitative PCR {#sec4.14}
----------------

RNA was isolated from macrophages, or from flow cytometry-sorted cells using the RNeasy Mini kit (QIAGEN, Manchester, UK) according to the manufacturer's instructions. cDNA synthesis was performed using High-Capacity cDNA Reverse Transcriptase (Applied Biosystems, Life Technologies, Paisley, UK). qPCR were performed using TaqMan gene expression assays (Life Technologies) and TaqMan Universal PCR master mix. qPCR were run on the CFX96 detection system (Bio-Rad Laboratories, Hemel Hempstead, UK) and gene expression for each sample were normalized to RPLPO for human reference gene or HPRT for mouse reference gene and the differences were determined using the 2ΔC(t) calculation.

Quantitation of cytokine secretion {#sec4.15}
----------------------------------

Calprotectin was measured by ELISA (Biolegend) in the culture supernatants of control and butyrate macrophages after 5 days of differentiation by ELISA accordingly to the manufacturer's instruction and normalized to the cell count.

Transfection of primary human macrophages {#sec4.16}
-----------------------------------------

The Accell SMARTpool siRNA were used to target human *S100A8*, *S100A9* and *HDAC3* for siRNA-mediated gene silencing in macrophages according to the manufacturer's instructions (Dharmacon).

Immunoblot {#sec4.17}
----------

Cells were lysed and the protein extract was quantified by BCA (Thermo Scientific). Equal amounts of total cell lysates (20 μg) was run on SDS-PAGE gels (4%--20%) (Bio-Rad), followed by transfer to polyvinylidene difluoride membranes. Proteins were detected using primary antibodies against LC3B (D11, Cell signaling), β-actin (13E5, Cell signaling), phospho-S6 ribosomal protein (Ser235 and/or 236) (D57.2.2E, Cell signaling), S100A8 (EPR3554, Abcam), acetylated-H3 (ab47915, Abcam) and acetylated-H4 (EPR16606, Abcam), P62 lck (clone 3/P62, BD bioscience) and detected using HRP-conjugated secondary antibodies.

Isolation of lymphoid and myeloid populations from human blood {#sec4.18}
--------------------------------------------------------------

PBMC from healthy donors were isolated as detailed above and stained for surface markers in PBS with 0.1% bovine serum albumin buffer allowing MACS enrichment and FACS sorting. CD4^+^ T cells were enriched by depleting CD8^+^, CD19^+^, CD56^+^ and CD14^+^ cells by MACS and then stained using anti-CD4, anti-CD45RA and anti-CD45RO to sort naive CD4^+^CD45RA^+^ and memory CD4^+^CD45RO^+^ T cells by FACS. B cells, CD8^+^ T cells and NK cells were sortedby FACS using anti-CD19^+^ for B cells, anti-CD8 for CD8^+^ T cells or anti-CD56^+^ for NK cells. CD141^high^ and CD1c^+^ DC populations were enriched by depleting CD3^+^, CD19^+^, CD56^+^ and CD14^+^ cells by MACS and FACS sorted to isolate HLA-DR^high^ CD11c^low^ CD141^high^ for CD141^+^ DC or HLA-DR^high^ CD11c^high^ CD141^-^ CD1c^+^ for CD1c^+^DC. All cells were sorted using an AriaIII flow cytometer (BD Biosciences) to a purity of \> 95%. CD14^+^ monocytes were obtained by anti-CD14 bead enrichment using MACS sort.

Experimental Model and Subject details {#sec4.19}
--------------------------------------

Animals were bred and maintained under specific pathogen-free conditions. Animal experiments were performed in accordance with the UK Scientific Procedures Act (1986) under a Project License (PPL) authorised by the UK Home Office. 8- to 12-week-old inbred female C57BL/6J were used for experiments and were bred and maintained at the University of Oxford. Mice were routinely screened for the absence of pathogens, and were kept in individually ventilated cages with environmental enrichment. For experiments involving infection and/or butyrate administration, all mice in individual cages received the same treatment. To reduce cage effects each treatment was given to more than one cage in each experiment.

Sodium butyrate treatment and infection {#sec4.20}
---------------------------------------

Mice received either saline, as a control, or sodium butyrate (150mM final concentration) (Sigma-Aldrich, St. Louis, MO) in their drinking water for 7 days before the sort of colonic macrophages at steady state. In case of *Salmonella Typhimurium 1344 def AroA* and *Citrobacter rodentium* infection, mice received saline as a control or sodium butyrate in drinking water for 5 days and 3 days respectively before infection. For the infection, mice were intragastrically gavaged with nalidixic acid resistant Citrobacter rodentium (ICC169) (1x10^9^) or Salmonella Typhimurium (1x10^9^). Mice weight was monitored throughout the duration of experiment (7 days for *Citrobacter rodentium* and 2 days for *Salmonella Typhimurium*).

Histology score {#sec4.21}
---------------

Samples of the proximal colon were collected and fixed in buffered 10% of 36% formalin solution to assess the severity of colitis. Haematoxylin and eosin (H&E) staining was performed on 4--5 μm paraffin-embedded sections and inflammation was assessed using previously published criteria ([@bib26]). Each sample was graded semiquantitatively based on the following features: cellular infiltration of the lamina propria, epithelial hyperplasia and goblet cell depletion, percentage of the section affected, and markers of severe inflammation (submucosal inflammation, crypt abscesses) from 0 to 4 in each of the 4 parameters. Samples were scored by two individuals blinded and scores for each criterion were added to give an overall score for each sample of 0--12.

Isolation of mouse colonic macrophages {#sec4.22}
--------------------------------------

Colons from 10 mice gavaged with PBS and with sodium butyrate were prepared as described ([@bib2]). Briefly colons were opened, lumenal content removed and washed, and tissue cut into pieces. Pieces were washed twice in RPMI-1640 medium supplemented with 5% fetal bovine serum and 5mM EDTA at 37°C with shaking to remove epithelial cells. Tissue was then digested in RPMI medium containing 1mg/mL type VIII collagenase (Sigma-Aldrich, Gillingham, UK), 0.5mg/mL DNase I and 5% fetal bovine serum. Cells were then layered on a 40/80% Percoll gradient, centrifuged, and the colonic leukocytes at the gradient interface were recovered and were stained in phosphate-buffered saline with 0.1% bovine serum albumin buffer with a combination of the following antibodies: CD45 (30-F11), CD11c (N418), MHCII (M5/114.15.2), F4/80 (BM8); CD103 (M290), CD11b (M1/70), CD64 (X54-5/7.1). Before the sort, DAPI was added to differentiate viable from dead cells. Macrophages were defined as (CD11b^+^ CD64^+^ F4/80^+^ MHCII^+^ CD103^-^) positive. All cells were sorted on a AriaIII (BD Biosciences) flow cytometer to a purity of \> 95%.

Bone marrow derived macrophages {#sec4.23}
-------------------------------

In brief, bone marrow was extracted from the femur of mice, washed, cells were counted and seeded at the concentration of 7x10^6^ per 10cm dish in 10 mL of RPMI supplemented with 50 ng/mL murine M-CSF with 10% FCS (Sigma-Aldrich), 100 U/mL penicillin, 100 μg/mL streptomycin, 30 mM HEPES for 7 days with or without butyrate (1mM).

Phagocytosis assay {#sec4.24}
------------------

Macrophage phagocytic activity was measured by two different methods: Firstly by using *Escherichia coli* (K-12 strain) BioParticles™, Alexa Fluor™ 488 conjugate as per manufracture\'s instruction; Secondly, macrophages were infected with GFP-*Salmonella* and incubated for indicated time (15 min, 30 min, 45 min, 60 min). Cells were washed and the fluorescence due to *Salmonella* attached to the outside of the cells was quenched with trypan blue solution (4%). The fluorescence was evaluated by flow cytometry.

Statistics {#sec4.25}
----------

Depending on the dataset, a Mann--Whitney nonparametric*-*test or Kruskal Wallis test (one-way Anova analysis) was used to calculate significance between groups. Graph generation and statistical analyses were performed using Prism version 5.0d software (GraphPad, La Jolla, CA). Differences were considered statistically significant when p \< 0.05.

Data and Software Availability {#sec4.26}
------------------------------

The accession number for the single cell sequencing reported in this paper is Gene Expression Omnibus: [GSE111049](ncbi-geo:GSE111049){#interref80}. This accession number will be accessible to readers upon publication of the manuscript.
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